Radiation Therapy and Concurrent Cisplatin Chemotherapy for Locally Advanced or Metastatic Malignant Melanoma
Stopped early · Phase 2
Conditions studied: Cancer, Melanoma
In brief
The study is a prospective phase II trial of radiation therapy concurrent with cisplatin chemotherapy in the treatment of locally advanced or metastatic melanoma in patients who are deemed to require radiation therapy by treating physicians for purposes of local control or palliation. Eligibility criteria include pathologically confirmed melanoma. Patients will undergo radiation therapy (20 treatments of 2.5 Gy for a total of 50 Gy) concurrent with cisplatin chemotherapy.
Key facts
- Study ID
- NCT00707161
- Run by
- University of Utah
- People needed
- 6
- Starts
- 2005-09-01
- Expected to finish
- 2010-02-01
- Last updated by the study team
- 2017-03-31
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Signed study-specific consent form prior to registration.
- Pathologically confirmed malignant melanoma.
- Measurable melanoma lesion deemed to require radiation by treating physicians for purposes of local control or palliation. The lesion may be the primary melanoma, a nodal metastasis, or a distant metastasis. Recurrent lesions are allowed.
- Lesion has to be measurable clinically or radiographically in 2 dimensions.
- Karnofsky Performance Scale (KPS) > 70.
- Laboratory values
- White blood cells (WBC) > 3000/mm3
- Absolute granulocyte count > 1,500
- Platelets > 100,000/mm3
- Total bilirubin < 2.0 x institutional upper limit of normal
- AST or ALT (aminotransferase/alanine aminotransferase) < 2.5 x institutional upper limit of normal
- Serum calcium < 1.3 x institutional upper limit of normal
- Serum creatinine < 1.5 mg/dL or Creatinine clearance > 50 cc/min,calculated as follows: CCr = 0.85 x (140-age) x (weight in kg) 72 x serum creatinine in mg/dL
You may not qualify if…
- Systemic therapy for malignant melanoma within one month preceding trial enrollment.
- Prior irradiation to the planned field.
- Concomitant chemotherapy (in addition to cisplatin) or biologic therapy is allowed.
- Significant infection or other co-existent medical condition which would prevent the use of full dose chemotherapy.
- Pre-existing sensory neuropathy (CTC 3.0 ≥ Grade II)
- Pregnancy or lactation.
Where it is running
- Huntsman Cancer Institute — Salt Lake City, Utah, United States
- LDS Hospital — Salt Lake City, Utah, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.